Akums Drugs Q2 FY27 Earnings Call — Analysis (NSE: AKUMS)
Akums posted strong Q2FY27 performance with revenue up 31.9% YoY to ₹1,342 Cr and EBITDA doubling to ₹195 Cr, driven by over 20% CDMO volume growth and margin expansion.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q2FY27 Consolidated Revenue ₹1,342 Cr ( +31.9% YoY ) . New guidance — FY28 domestic branded segment growth… growth on par with IPM . New story: Sustained CDMO Volume Growth .
Results
Revenue ₹1,342 Cr (+31.9% YoY); EBITDA ₹195 Cr (+106.0% YoY, 14.5% margin); PAT ₹115 Cr (+168.3% YoY).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹1,342 Cr | +31.9% | yoy · Q2FY27 |
| Consolidated Revenue | ₹1,342 Cr | +15.1% | sequential · Q2FY27 |
| Consolidated EBITDA | ₹195 Cr | +106.0% | yoy · Q2FY27 |
| Consolidated EBITDA Margin | 14.5% | +520bps | yoy · Q2FY27 · vs 9.3% in Q2FY26 |
| Profit After Tax | ₹115 Cr | +168.3% | yoy · Q2FY27 |
| CDMO Revenue | ₹1,115 Cr | +38.6% | yoy · Q2FY27 |
| CDMO EBITDA | ₹168 Cr | +99.6% | yoy · Q2FY27 |
| Domestic Branded Revenue | ₹132 Cr | +8.2% | yoy · Q2FY27 |
| Domestic Branded EBITDA | ₹24 Cr | -8.9% | yoy · Q2FY27 |
| International Branded Revenue | ₹44 Cr | +95.2% | yoy · Q2FY27 |
| API Revenue | ₹29 Cr | -35.3% | yoy · Q2FY27 |
| API EBITDA | -₹5.7 Cr | +59.3% | yoy · Q2FY27 · Loss narrowed vs -₹14 Cr in Q2FY26 |
| Trade Generics Revenue | ₹23 Cr | -5.4% | yoy · Q2FY27 |
| Cash and Cash Equivalents | ₹1,680 Cr | point_in_time · Q2FY27 · Sep-26 | |
| H1 Free Cash Flow | ₹45.5 Cr | point_in_time · H1FY27 · H1FY27 after capex/acquisitions |
Guidance
Baddi Phase 1 (6B tablets) to operationalise by Q1FY28, while Zambia export revenue ($25M) will be booked in Q1FY28 and European CDMO supplies begin in FY28.
What management committed to
- The new Baddi facility's oral solids Phase 1, with an annual capacity of over 6 billion units, will fully operationalize by Q1 FY28. — fully operational, Q1 FY28
- Supplies from the European CDMO project will commence in FY28. — commenced, FY28
- Revenue from the initial $25 million Zambia supply order will be booked in Q1 FY28 following dispatch in Q4 FY27 and approximately 120 days shipping time. — revenue booked, Q1 FY28
- The domestic branded formulations segment will deliver revenue growth on par with the Indian Pharma Market (IPM) average growth rate by FY28. — growth on par with IPM, FY28
- The API segment will achieve EBITDA breakeven over the next 3 to 4 quarters (by approximately Q2 or Q3 FY28). — breakeven (EBITDA >= 0), Q2/Q3 FY28
- Following the delivery of the initial $25 million order, the Government of Zambia will commit to a second $25 million round of supplies. — $25 million supply commitment, FY28-FY29
- Akums expects to commercialize the over 30 products currently in R&D for regulated markets over the next 3 to 4 years (by FY30-FY31). — over 30 products, FY30-FY31
Key themes
CDMO volume momentum and global expansion
How the narrative shifted
- Sustained CDMO Volume Growth: Positioning consistent high-teens volume growth (over 20% for 4 quarters) as a structural competitive advantage of the CDMO business model and a proven execution track record.
- Zambia Commercial Milestone (Delayed Revenue Recognition): Confirming the $25 million contract is fully intact, explaining the shift in revenue recognition to Q1 FY28 due to political election timelines and long shipping lead times (ex-works vs delivered basis).
- Europe CDMO Path to Commercialization: Highlighting the dossier filing as the key de-risking milestone for the European project, positioning FY28 supply commencement as imminent pending regulatory approval.
- Capacity Expansion at Baddi: Executing a phased large-scale capex plan to add 12 billion tablets of oral solids capacity, reinforcing commitment to long-term CDMO market leadership.
- API Segment Turnaround Path: Acknowledging persistent losses (INR 5.7 cr EBITD loss in Q2) while guiding towards breakeven in 3-4 quarters through product mix improvement (higher gross margin products) and geographic diversification (CEPs, EDQM audit).
- Input Material Cost & API Price Pressure: Acknowledging rising input costs (API +5-7% YoY, husk/solvents up) as a persistent external headwind, but implicitly signalling CDMO pass-through capability given stable margins.
- Beauty & Personal Care Diversification (Oriflame): Positioning the Oriflame plant acquisition as a strategic platform into the fast-growing beauty and personal care category, with a medium-term 3x revenue on investment target.
Operational commentary
- Successfully integrated 2 manufacturing plants acquired from Oriflame (₹56 Cr acquisition) to enter beauty and personal care/color cosmetics CDMO.
- Baddi Phase 1 facility for oral solids (6 billion units annual capacity) to be fully operationalized by Q1FY28, taking total oral solids capacity towards 57B units.
- Zambia JV received purchase orders for $25M commercial supplies; manufacturing underway with dispatches in Q4FY27 and delivery/revenue recognition in Q1FY28.
- European CDMO contract dossier filed with regulatory approvals expected in 1-2 quarters; commercial supplies targeted for FY28.
- Domestic branded business expanded field force to 1,600 MRs (added 200 personnel in Q1), temporarily pulling overall PCPM to 2.5 while mature gynae divisions remain above 3.2.
Analyst Q&A
Q. What is the accounting and revenue recognition timeline for the European contract advance?
Revenue recognition will begin when plant and dossier approvals are received, and supplies start, spreading the advance proportionately over the contract period rather than recognizing it upfront.
Q. What is the capex outlook for the next 3 years?
Management cited H1 capex of ₹210 Cr (including Oriflame ₹56 Cr and Baddi ₹43 Cr) with baseline maintenance capex around ₹100 Cr (5% of gross block), but did not provide a consolidated multi-year forward annual capex figure.
Q. What is the status of the NPPA show cause notice (158BC) for FY19-25?
The notice relates to job work manufacturing for a marketing partner whose contract explicitly assigns NPPA liability to the partner, resulting in zero financial liability or provisioning for Akums.
Research and educational content only. Not investment advice.